LIMINATUS PHARMA, INC. Basic Shares Outstanding (Weighted Average)
LIMINATUS PHARMA, INC. (LIMN) reported Basic Shares Outstanding (Weighted Average) of 48.40 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-14
- LIMINATUS PHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 48.40M shares, a 107.71% increase year-over-year.
- LIMINATUS PHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 36.00M shares, a 105.71% increase year-over-year.
- LIMINATUS PHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 27.10M shares, a 54.86% increase year-over-year.
- LIMINATUS PHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 27.01M shares, a 54.33% increase year-over-year.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 48.40M shares 10-Q · filed 2026-08-14 | 42.23M shares 10-Q · filed 2026-08-14 | 37.17M shares derived: average of 3 quarters · filed 2026-08-14 | 34.63M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | 36.00M shares S-1 · filed 2026-06-24 | 31.55M shares derived: average of 2 quarters · filed 2026-06-24 | 30.04M shares derived: average of 3 quarters · filed 2026-06-24 | 28.35M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | 27.10M shares derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | 27.05M shares derived: average of 2 quarters · filed 2026-06-24 | 25.80M shares derived: average of 3 quarters · filed 2026-08-14 | 23.75M shares S-1 · filed 2026-06-24 | |
| 2025-09-30 | 27.01M shares 10-Q · filed 2025-11-14 | 25.15M shares derived: average of 2 quarters · filed 2026-08-14 | 22.64M shares 10-Q · filed 2025-11-14 | 21.33M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | 23.30M shares 10-Q · filed 2026-08-14 | 20.40M shares 10-Q · filed 2026-08-14 | 19.43M shares derived: average of 3 quarters · filed 2026-08-14 | 18.95M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | 17.50M shares S-1 · filed 2026-06-24 | 100.00 shares 10-Q · filed 2025-06-02 | 17.50M shares derived: average of 2 quarters · filed 2026-06-24 | 17.50M shares derived: average of 3 quarters · filed 2026-06-24 | 17.50M shares derived: average of 4 quarters · filed 2026-06-24 |
| 2024-12-31 | 17.50M shares derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | 17.50M shares derived: average of 2 quarters · filed 2026-06-24 | 17.50M shares derived: average of 3 quarters · filed 2026-06-24 | 17.50M shares S-1 · filed 2026-06-24 | |
| 2024-09-30 | 17.50M shares 10-Q · filed 2025-11-14 | 17.50M shares derived: average of 2 quarters · filed 2025-11-14 | 17.50M shares 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | 17.50M shares 10-Q · filed 2025-10-06 | 17.50M shares 10-Q · filed 2025-10-06 | |||
| 2024-03-31 | 100.00 shares 10-Q · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |